These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 21600381

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer.
    Burstein HJ.
    Semin Oncol; 2011 Jun; 38 Suppl 2():S1-2. PubMed ID: 21600379
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A.
    Bull Cancer; 2012 Apr 01; 99(4):441-51. PubMed ID: 22450359
    [Abstract] [Full Text] [Related]

  • 7. PARP inhibitors in breast cancer.
    Telli ML, Ford JM.
    Clin Adv Hematol Oncol; 2010 Sep 01; 8(9):629-35. PubMed ID: 21157412
    [Abstract] [Full Text] [Related]

  • 8. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y, Calvert H.
    Ann N Y Acad Sci; 2008 Sep 01; 1138():136-45. PubMed ID: 18837894
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.
    J Natl Cancer Inst; 2011 Feb 16; 103(4):334-46. PubMed ID: 21183737
    [Abstract] [Full Text] [Related]

  • 10. [PARP inhibitors for cancer therapy].
    Saito H, Miki Y.
    Gan To Kagaku Ryoho; 2011 Jan 16; 38(1):12-8. PubMed ID: 21368455
    [Abstract] [Full Text] [Related]

  • 11. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR, Borges VF, Eckhardt SG, Jimeno A.
    Drug News Perspect; 2009 Dec 16; 22(10):603-8. PubMed ID: 20140280
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. PARP inhibition in breast cancer.
    Garber J.
    Clin Adv Hematol Oncol; 2009 Sep 16; 7(9):573-5. PubMed ID: 20020667
    [No Abstract] [Full Text] [Related]

  • 15. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.
    Hiscox S, Morgan L, Green T, Nicholson RI.
    Endocr Relat Cancer; 2006 Dec 16; 13 Suppl 1():S53-9. PubMed ID: 17259559
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 18. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
    Mayer EL, Krop IE.
    Clin Cancer Res; 2010 Jul 15; 16(14):3526-32. PubMed ID: 20634194
    [Abstract] [Full Text] [Related]

  • 19. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS.
    J Natl Cancer Inst; 2009 Sep 16; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract] [Full Text] [Related]

  • 20. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD.
    Curr Opin Drug Discov Devel; 2010 Sep 16; 13(5):577-86. PubMed ID: 20812149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.